Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression

American Journal of Pathology

Volumn 163, Issue 3, 2003, Pages 1013-1020

  Schraml, Peter ^a   Hergovitz, Alexander ^b   Hatz, Florian ^a   Amin, Mahul B ^c   Lim, So D ^c   Krek, Wilhelm ^b   Mihatsch, Michael J ^a   Moch, Holger ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0042425755     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63461-X     Document Type: Article

References (45)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan D-SR, Dean M, Glavac D, Richards F, Crossey P, Ferguson-Smfth MA, LePaslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Lineham WM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor-suppressor gene. Science 1993, 260:1317-1320
2. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky J, Duan DR, Florence C, Potatti R, Walther MM, Bander NH, Grossman HB, Brach H, Pomer S, Brooks JD, Issacs WB, Lerman MI, Zber B, Lineham WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90
3. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, Decker HJ: VHL alterations in human clear-cell renal-cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000, 60:1942-1948
4. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, Moch H: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear-cell renal-cell carcinoma J Pathol 2002, 196:186-193
5. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, Zbar I B: Suppression of growth of renal carcinoma cells by/the von Hippel-Lindau tumor-suppressor gene. Cancer Res 1995, 55:4804-4807
6. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109
7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 1999, 399:271-275
8. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O: The von Hippel-Lindau tumor-suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998, 1:959-968
9. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W: Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003, 5:64-70
10. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W: The von Hippel-Lindau tumor-suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999, 13:1822-1833
11. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxial-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-427
12. Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor-suppressor protein. EMBO J 2000, 19:4298-14309
13. Iliopoulos O, Ohh M, Kaelin WG Jr: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998, 95:11661-11666
14. Sakashita N, Takeya M, Kishida T, Stackhouse TM, Zbar B, Takahashi K: Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem J 1999, 31:133-144
15. Ye Y, Vasavada S, Kuzmin I, Stackhouse T, Zbar B, Williams BR: Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer 1998, 78:62-69
16. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE: Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996, 75:231-238
17. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 1997, 28:459-464
18. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847
19. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Scholzau A, Kononen J, Sauter G: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 2001, 93:1141-1146
20. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M Kallioniemi OP, Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001, 159:2249-2256
21. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G: High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal-cell carcinoma. Am J Pathol 1999, 154:981-986
22. Thoenes W, Stoerkel S, Rumpelt H: Histopathology and classification of renal cell tumors (adenomas oncocylomas, and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986, 181:125-143
23. UICC: TNM Classification of Malignant Tumours. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto, Wiley-Liss, 1997
24. Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, Wilber K, Kononen J, Sauter G, Mihatsch MJ, Moch H: CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor-suppressor gene proximal to CDKN2A. Am J Pathol 2001, 158:593-601
25. Schraml P, Muller D, Bednar R, Gasser T, Sauter G, Mihatsch MJ, Moch H: Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J Pathol 2000, 190:457-461
26. Brieger J, Weidt EJ, Schirmacher P, Storkel S, Huber C, Decker HJ: Inverse regulation of vascular endothelial growth factor and VHL tumor-suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. J Mol Med 1999, 77:505-510
27. Lee S, Neumann M, Stearman R, Stauber R, Pause A, Pavlakis GN, Klausner RD: Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor-suppressor protein. Mol Cell Biol 1999, 19:1486-1497
28. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner LJ, Forster T, Kononen J, Fijan A, Bruderer J, Schmid LJ, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001, 194:349-357
29. Rubin MA, Dunn R, Strawderman M, Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002, 26:312-319
30. Los M, Zeamari S, Foekens JA, Gebbink MF, Voest EE: Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor-suppressor gene. Cancer Res 1999, 59:4440-4445
31. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ: Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000, 89:604-614
32. Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD: Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor-suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 1996, 93:1770-1775
33. Gronwald J, Storkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, Lubinski J, Cremer T: Comparison of DNA gains and losses in primary renal clear-cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res 1997, 57:481-487
34. Gronwald J, Hadaczek P, Storkel S, Holtgreve-Grez H, Rabbitts P, Cremer T, Lubinski J: Molecular evidence for derivation of metastatic cells from minor subclones of primary clear renal cell carcinomas Cancer Detect Prev 1999, 23:479-484
35. Bissig H, Richter J, Desper R, Meier V, Schraml P, Schäffer A, Sauter G, Mihatsch M, Moch H: Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization Am J Pathol 1999, 155:267-274
36. Velickovic M, Delahunt B, Grebe SK: Loss of heterozygosity at 3p14.2 in clear-cell renal-cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 1999, 59:1323-1326
37. Speicher M, Schoell B, Du Manoir S, Schröck E, Ried T, Cremer T, Stoerkel S, Kovacs A, Kovacs G: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994, 145:356-364
38. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G: Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996, 179:157-161
39. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor-suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852-2855
40. Jiang F, Moch H, Richter J, Gasser T, Gschwind R, Egenter C, Bubendorf L, Sauter G, Mihatsch M: Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal cell carcinomas with sarcomatoid transformation. J Pathol 1998, 185:382-388
41. Presti J, Reuter V, Cordon-Cardo C, Mazumdar M, Fair W, Jhanwar S: Allelic deletions in renal tumors: histopathological correlations. Cancer Res 1993, 53:5780-5783
42. Velickovic M, Delahunt B, Storkel S, Grebem SK: VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance Cancer Res 2001, 61:4815-4819
43. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91:9700-9704
44. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP: The von Hippel-Lindau tumor-suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997, 17:5629-5639
45. Kuzmin I, Duh FM, Latif F, Geil L, Zbar B, Lerman MI: Identification of the promoter of the human von Hippel-Lindau disease tumor-suppressor gene Oncogene 1995, 10:2185-2194